TNFSF4

TNF superfamily member 4, the group of CD molecules|Tumor necrosis factor superfamily

Basic information

Region (hg38): 1:173162645-173477583

Previous symbols: [ "TXGP1" ]

Links

ENSG00000117586NCBI:7292OMIM:603594HGNC:11934Uniprot:P23510AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TNFSF4 gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TNFSF4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
1
clinvar
2
missense
4
clinvar
1
clinvar
5
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
0
Total 0 0 4 2 1

Variants in TNFSF4

This is a list of pathogenic ClinVar variants found in the TNFSF4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-173186569-C-T not specified Uncertain significance (Nov 07, 2023)3180336
1-173186590-G-A Likely benign (Apr 03, 2018)747383
1-173186683-G-C not specified Uncertain significance (Dec 19, 2022)2337049
1-173186721-C-T not specified Uncertain significance (Dec 12, 2023)2334384
1-173186806-C-T not specified Uncertain significance (Dec 13, 2022)2334228
1-173188537-G-A Benign (Jun 18, 2018)772822
1-173188559-C-T not specified Likely benign (Aug 10, 2021)2405313
1-173477402-C-T not specified Uncertain significance (Feb 03, 2022)2275583
1-173477431-C-T not specified Uncertain significance (Jun 03, 2024)3309854
1-173477439-T-G not specified Uncertain significance (Aug 30, 2021)2340325
1-173477447-A-G not specified Uncertain significance (May 09, 2024)3309853

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TNFSF4protein_codingprotein_codingENST00000281834 323580
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.04940.702125344021253460.00000798
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.9256893.10.7300.000004371202
Missense in Polyphen1025.1270.39798331
Synonymous0.5803438.60.8810.00000180355
Loss of Function0.65123.270.6111.39e-739

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002910.0000291
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00001020.00000882
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production.;
Disease
DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. {ECO:0000269|PubMed:18059267}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. The upstream region of TNFSF4 contains a single risk haplotype for SLE, which is correlated with increased expression of both cell-surface TNFSF4 and TNFSF4 transcripts. Increased levels of TNFSF4 are thought to augment T-cell-APC interaction and the functional consequences of T-cell activation, thereby destabilizing peripheral tolerance.;
Pathway
Cytokine-cytokine receptor interaction - Homo sapiens (human);Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway;Vitamin D Receptor Pathway;TNFR2 non-canonical NF-kB pathway;Cytokine Signaling in Immune system;Immune System;TNFs bind their physiological receptors (Consensus)

Recessive Scores

pRec
0.308

Intolerance Scores

loftool
0.273
rvis_EVS
-0.23
rvis_percentile_EVS
36.86

Haploinsufficiency Scores

pHI
0.258
hipred
N
hipred_score
0.215
ghis
0.608

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.0681

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Tnfsf4
Phenotype
immune system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
defense response to nematode;acute inflammatory response;positive regulation of T cell cytokine production;regulation of adaptive immune response;positive regulation of type 2 immune response;positive regulation of immunoglobulin mediated immune response;inflammatory response;immune response;signal transduction;positive regulation of cell population proliferation;response to virus;regulation of signaling receptor activity;negative regulation of interferon-gamma production;negative regulation of interleukin-17 production;positive regulation of interferon-gamma production;positive regulation of interleukin-10 production;positive regulation of interleukin-12 production;positive regulation of interleukin-13 production;positive regulation of interleukin-4 production;positive regulation of interleukin-6 production;tumor necrosis factor-mediated signaling pathway;memory T cell activation;T-helper 2 cell activation;response to nitrogen dioxide;positive regulation of CD4-positive, alpha-beta T cell differentiation;positive regulation of memory T cell differentiation;negative regulation of DNA-binding transcription factor activity;negative regulation of regulatory T cell differentiation;negative regulation of T-helper 1 cell differentiation;positive regulation of T-helper 2 cell differentiation;negative regulation of transcription, DNA-templated;positive regulation of alpha-beta T cell proliferation;regulation of inflammatory response;positive regulation of inflammatory response;positive regulation of B cell activation;positive regulation of immunoglobulin secretion;cellular response to lipopolysaccharide;cellular response to prostaglandin E stimulus;chemokine (C-C motif) ligand 11 production;positive regulation of CD4-positive, alpha-beta T cell costimulation;positive regulation of interleukin-4-dependent isotype switching to IgE isotypes
Cellular component
extracellular space;plasma membrane;integral component of plasma membrane;cell surface
Molecular function
signaling receptor binding;cytokine activity;tumor necrosis factor receptor binding;protein binding;tumor necrosis factor receptor superfamily binding